Samrat Pharmachem Peer Comparison

Samrat Pharmachem Ltd. exhibits significant underperformance across key financial metrics compared to its peers, particularly in growth and profitability. However, its low PE ratio presents it as a potential value pick for investors willing to take on higher risk. Among its peers, companies like Cipla and Dr. Reddy's Laboratories stand out as strong performers in profitability and growth.

• • Samrat Pharmachem shows zero revenue growth and earnings, indicating stagnation.
• • Cipla leads with a 13.28% YoY revenue growth and a solid EPS of 66.76.
• • Dr. Reddy's and Mankind Pharma demonstrate strong profitability metrics with high ROE and margins.
• • Sun Pharmaceutical Industries is significantly overvalued with a high PE of 87.59 despite decent growth.
• • Financially, Samrat Pharmachem presents a low debt equity ratio, which is a positive signal.

• • Cipla Ltd.: Strong revenue growth of 13.28% YoY and solid profitability metrics including a 16.63% ROE.
• • Dr. Reddy's Laboratories Ltd.: High profitability with a 21.76% ROE and 16.54% revenue growth YoY.
• • Mankind Pharma Ltd.: Rapid growth with an 18.12% YoY revenue increase and solid margins.